Post
Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy – The Guardian
- Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy The Guardian
- Veracyte genomic test identifies breast cancer patients who can skip chemo Reuters
- Genetic test could offer breast cancer patients chance to skip chemo The Times
- Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy Business Wire
- OPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy Docwire News